Selecta Biosciences (SELB) Misses Q4 EPS by 2c, Revenues Beat

Selecta Biosciences (NASDAQ: SELB) reported Q4 EPS of ($0.14), $0.02 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $12 million versus the consensus estimate of $6.37 million.

“This is a very exciting time in Selecta’s history, having made significant progress across all aspects of the company,” said Carsten Brunn, Ph.D., president and chief executive officer of Selecta. “In 2020, we significantly de-risked the company through a strategic partnership with Sobi for SEL-212, under which we commenced the Phase 3 DISSOLVE program in the third quarter of 2020. We rapidly advanced our pipeline, having recently dosed our first subject with ImmTOR in combination with an AAV capsid, which builds on compelling non-human primate data announced earlier this year.”

“We are very pleased by the continued progress of our gene therapy program. In collaboration with AskBio, our lead program in methylmalonic acidemia, is on track to enter the clinic in the second quarter of this year and we expect initial data by the end of the year. A key objective of 2021 will be to generate human data in our gene therapy programs and to continue to build our extensive pipeline in gene therapies, enzyme therapies—with an expected IND filing by the end of the year in IgA nephropathy—and autoimmune diseases, as we work to deliver on our mission to leverage our pioneering ImmTOR platform to improve the lives of patients and their families,” Dr. Brunn added.

For earnings history and earnings-related data on Selecta Biosciences (SELB) click here.

You May Also Be Interested In

• Nanometrics (NANO) Issues Business Update, Reports FY23 Results
• Ball Corporation (BALL) Raises Dividend, Enters 40M Share Buyback, Announces Management Changes
• SLM (SLM) Tops Q1 EPS by 20c; offers guidance